Erratum: Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) (Oncotarget (2015) 6 (22496-22512) DOI: 10.18632/oncotarget.4318)

Abstract

This article has been corrected: Due to an entry error found in one of the triplicate data for the 48-h time-point of stability in human serum in vitro, the half-life for drug release has been corrected to 18.82 h from the stated 23.98 h in Figure 1C. The corrected Figure 1C is shown below. The authors declare that these corrections do not change the results or conclusions of this paper. (Figure Presented).